Literature DB >> 12367693

Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.

Jingduan Chi1, Anura L Jayewardene, Judith A Stone, Toshiro Motoya, Francesca T Aweeka.   

Abstract

A sensitive and rapid liquid chromatography tandem mass spectrometry (LC-MS-MS) method has been developed to measure the levels of five HIV protease inhibitors nelfinavir (NFV), indinavir (IDV), ritonavir (RTV), saquinavir (SQV) and amprenavir (APV) in human plasma. The analytes and internal standard are isolated from plasma by a simple acetonitrile precipitation of plasma proteins followed by centrifugation. LC-MS-MS in positive mode used pairs of ions at m/z of 568.4/330.0, 614.3/421.2, 720.9/296.0, 671.1/570.2 and 505.9/245.0 for NFV, IDV, RTV, SQV and APV, respectively and 628/421 for the internal standard. Two 1/x weighted linear calibration curves for each analyte were established for quantitation with the low curve ranging from 5 to 1000 ng/ml and while the high curve ranging from 1000 to 10,000 ng/ml. Mean inter- and intra-assay coefficients of variation (CVs) over the ranges of the standard curves were less than 10%. The overall recovery of NFV, IDV, RTV, SQV and APV were 88.4, 91.4, 92.2, 88.9 and 87.6%, respectively. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12367693     DOI: 10.1016/s0731-7085(02)00357-6

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  13 in total

1.  UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.

Authors:  Jiangeng Huang; Nagsen Gautam; Sai Praneeth R Bathena; Upal Roy; JoEllyn McMillan; Howard E Gendelman; Yazen Alnouti
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-07-01       Impact factor: 3.205

2.  Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy.

Authors:  Nonhlanhla N Mkhize; Pamela P Gumbi; Lenine J Liebenberg; Yuan Ren; Peter Smith; Lynette Denny; Jo-Ann S Passmore
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

3.  Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice.

Authors:  Manuela Pereira de Oliveira; Emmanuel Garcion; Nicolas Venisse; Jean-Pierre Benoit; William Couet; Jean-Christophe Olivier
Journal:  Pharm Res       Date:  2005-11       Impact factor: 4.200

4.  The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.

Authors:  Tanuja N Gengiah; Nicholas H G Holford; Julia H Botha; Andrew L Gray; Kogieleum Naidoo; Salim S Abdool Karim
Journal:  Eur J Clin Pharmacol       Date:  2011-11-23       Impact factor: 2.953

5.  Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?

Authors:  Catherine Orrell; Karen Cohen; Francesca Conradie; Jennifer Zeinecker; Prudence Ive; Ian Sanne; Robin Wood
Journal:  Antivir Ther       Date:  2011

6.  Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

Authors:  Ighovwerha Ofotokun; Lumine H Na; Raphael J Landovitz; Heather J Ribaudo; Grace A McComsey; Catherine Godfrey; Francesca Aweeka; Susan E Cohn; Manish Sagar; Daniel R Kuritzkes; Todd T Brown; Kristine B Patterson; Michael F Para; Randi Y Leavitt; Angelina Villasis-Keever; Bryan P Baugh; Jeffrey L Lennox; Judith S Currier
Journal:  Clin Infect Dis       Date:  2015-03-12       Impact factor: 9.079

7.  Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.

Authors:  Karen Cohen; Alison Grant; Collet Dandara; Helen McIlleron; Lindiwe Pemba; Katherine Fielding; Salome Charalombous; Gavin Churchyard; Peter Smith; Gary Maartens
Journal:  Antivir Ther       Date:  2009

8.  Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects.

Authors:  Ping Liu; Grover Foster; Kuan Gandelman; Robert R LaBadie; Mark J Allison; Maria J Gutierrez; Amarnath Sharma
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

9.  Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding.

Authors:  Monica Gandhi; Julia Mwesigwa; Francesca Aweeka; Albert Plenty; Edwin Charlebois; Theodore D Ruel; Yong Huang; Tamara Clark; Veronica Ades; Paul Natureeba; Flavia A Luwedde; Jane Achan; Moses R Kamya; Diane V Havlir; Deborah Cohan
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

10.  Protease inhibitor levels in hair strongly predict virologic response to treatment.

Authors:  Monica Gandhi; Niloufar Ameli; Peter Bacchetti; Stephen J Gange; Kathryn Anastos; Alexandra Levine; Charles L Hyman; Mardge Cohen; Mary Young; Yong Huang; Ruth M Greenblatt
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.